Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rainmed MedicalHKSE:02297 47 Buyback Yield % is 0.00 as of Aug. 31, 2026. GuruFocus rates HKSE:02297 with a GF Score™ of 47/100 and a GF Value™ of HK$0.08 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 326 Medical Devices & Instruments companies, Rainmed Medical ranks worse than 306748.16% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Rainmed Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02297 vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Rainmed Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rainmed Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rainmed Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Rainmed Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rainmed Medical (HKSE:02297) has a Buyback Yield % of 0.00 as of Aug. 31, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rainmed Medical and its competitors. According to the industry distribution chart, Rainmed Medical ranks #999999 out of 326 companies in the Medical Devices & Instruments industry.
Is Rainmed Medical's Buyback Yield % too high?
Rainmed Medical's current Buyback Yield % is 0.00. Based on the distribution chart, Rainmed Medical ranks #999999 out of 326 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Rainmed Medical has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Rainmed Medical ranks #999999 out of 326 companies for Buyback Yield %. This places Rainmed Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rainmed Medical and its competitors. Rainmed Medical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.20 — trading 143.8% above its estimated fair value. The current Buyback Yield % is 0.00. Rainmed Medical's overall GF Score™ is 47/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current Buyback Yield % is 0.00 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rainmed Medical (HKSE:02297) Overvalued in 2026?
Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued.
The current stock price of HK$0.20 is trading 143.8% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Rainmed Medical to be Significantly Overvalued.
Key valuation signals for HKSE:02297:
Buyback Yield %: 0.00
GF Value™: HK$0.08 vs. price of HK$0.20 (143.8% above fair value)
No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
47GF Score
Get the complete analysis for HKSE:02297
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02297 has been successfully added to your 
